



Drug Therapy Protocols: Fentanyl and midazolam (combined)

Policy code	DTP_FEMI_0722
Date	July, 2022
Purpose	To ensure a consistent procedural approach to fentanyl and midazolam (combined).
Scope	Applies to all Queensland Ambulance Service (QAS) clinical staff.
Health care setting	Pre-hospital assessment and treatment.
Population	Applies to all ages unless specifically mentioned.
Source of funding	Internal – 100%
Author	Clinical Quality & Patient Safety Unit, QAS
Review date	July, 2024
Information security	UNCLASSIFIED – Queensland Government Information Security Classification Framework.
URL	https://ambulance.qld.gov.au/clinical.html

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by appropriately qualified QAS clinicians when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

© State of Queensland (Queensland Ambulance Service) 2022.



This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

For copyright permissions beyond the scope of this license please contact: Clinical.Guidelines@ambulance.qld.gov.au

Fentanyl and midazolam (combined)

July, 2022

Drug class^[1,2]

- Narcotic analgesic
- Benzodiazepine

Pharmacology^[1,2]

Fentanyl is a synthetic narcotic analgesic altering the perception and emotional response to pain. Midazolam is a CNS depressant that induces amnesia, anaesthesia and sedation. In addition to these individual properties, the combination provides synergistic sedative effects.

Metabolism

Hepatic metabolism, renal excretion.

Indications

- Sedation for the maintenance of an established ETT/SAD (when transport is longer than 30 minutes)

Contraindications

- Allergy AND/OR Adverse Drug Reaction

Precautions

- Haemodynamic instability
- Reduced dosages must be considered in low body weight, older or frail patients
- Excessive sedation may impair neurological assessment at the receiving medical facility
- Accumulation of active metabolites

Side effects^[1,2]

- Hypotension
- Respiratory depression
- Muscular rigidity (particularly muscles of respiration)

Presentation

- Ampoule, 100 microg/2 mL *fentanyl*
- Ampoule, 5 mg/1 mL *midazolam*

Onset	Duration	Half-life
< 5 minutes	Several hours	≈ 2 hours

Schedule

- Fentanyl – S8 (Controlled drugs).
- Midazolam – S4 (Restricted drugs).

Routes of administration

Intravenous infusion (IV INF) CCP

Special notes

- Ambulance officers must only administer medications for the listed indications and dosing range. Any considerations for treatment outside the listed scope of practice requires mandatory approval via the *QAS Clinical Consultation and Advice Line*.
- Fentanyl & midazolam infusions must be administered through a dedicated line.
- Patients on fentanyl & midazolam infusions must have their NIBP measured regularly (every 5 mins at a minimum).
- The optimal sedation target is a patient who is not responsive to simple stimuli (e.g. gentle patient movement) however will respond to painful stimuli.
- NIBP cuffs must not be placed on limbs with infusions to ensure flow is not obstructed.

Adult dosages^[1-6]

Sedation for the maintenance of an established ETT/SAD (when transport is longer than 30 minutes)

CCP

IV/IO
INF

Commence infusion at **50 microg fentanyl : 5 mg midazolam/hour (5mL/hr)** – titrate accordingly to indication and the patient's physiological response to treatment.

Consider PRN use of the bolus function if clinically appropriate.

Infusion preparation: Mix 200 microg fentanyl (4 mL) with 20 mg midazolam (4 mL) with 12 mL of sodium chloride 0.9% in a 20 mL syringe to achieve a final concentration of 200 microg fentanyl : 20 mg midazolam in 20 mL. Ensure syringe is appropriately labelled. Administer infusion via Perfusor® Space Medication Library (Fent 200/Midaz 20-Adult).

Paediatric dosages^[1-6]

Sedation for the maintenance of an established ETT/SAD (when transport is longer than 30 minutes)

CCP

IV/IO
INF

QAS Clinical Consultation and Advice Line consultation and approval required in all situations.

Infusion preparation: Mix 200 microg fentanyl (4 mL) with 20 mg midazolam (4 mL) with 12 mL of sodium chloride 0.9% in a 20 mL syringe to achieve a final concentration of 200 microg fentanyl: 20 mg midazolam in 20 mL. Ensure syringe is appropriately labelled. Administer infusion via Perfusor® Space Medication Library (Fent 20/Midaz 20-Paed).